Navigating the Tumor Microenvironment with Nano-Therapeutics: Advances and Challenges in Cancer Treatment

Pratik Singh

doi:10.52228/JRUB.2024-37-2-19

Journal of Ravishankar University

Pt. Ravishankar Shukla University, Raipur, Chhattisgarh

PART-B

(SCIENCE)

ISSN: 0970-5910

Abstract View

Submit Article

Navigating the Tumor Microenvironment with Nano-Therapeutics: Advances and Challenges in Cancer Treatment

Author(s): Pratik Singh

Email(s): pratikkshatri1234@gmail.com

Address: Rungta College of pharmaceutical science and research Bhilai, Chhattisgarh.
Formulation Research & Development –Non-Orals, Sun Pharmaceutical Industries Ltd, Vadodara, 390020, Gujarat, India.
*Corresponding Author: pratikkshatri1234@gmail.com

Published In: Volume - 37, Issue - 2, Year - 2024

DOI: 10.52228/JRUB.2024-37-2-19

View HTML

View PDF

ABSTRACT:
The tumor microenvironment (TME) is a critical determinant of cancer progression and therapeutic resistance. Recent advances in nanotechnology offer promising strategies to overcome the challenges posed by the TME, particularly in enhancing drug delivery and improving treatment efficacy. This review examines the composition and dynamics of the TME, emphasizing the complex interactions between cancer cells, stromal cells, immune components, and extracellular matrix factors that contribute to tumor growth and metastasis. Nanotherapeutics, with their ability to target the TME specifically, provide a unique opportunity to bypass the barriers that hinder traditional cancer therapies, such as hypoxia, acidity, and dense extracellular matrices. By exploring both passive and active targeting mechanisms, this review highlights the role of nanomaterials, such as liposomes, polymeric nanoparticles, and metallic nanoparticles, in overcoming these barriers and improving therapeutic outcomes. It also discusses the integration of nanotechnology with immunotherapies and other treatment modalities, enhancing immune responses and modulating the TME. Despite significant progress, challenges remain in the clinical translation of these nano-therapeutics. These include issues related to heterogeneity within the TME, resistance mechanisms, and the potential toxicity of nanomaterials. The review also covers the latest clinical trials, offering a comprehensive view of the current landscape and future directions for nano-based cancer therapies. By synthesizing recent research, this review provides valuable insights into the potential of nanomedicine in revolutionizing cancer treatment strategies, addressing key challenges, and improving patient outcomes.

Keywords:

Cite this article:
Singh (2024). Navigating the Tumor Microenvironment with Nano-Therapeutics: Advances and Challenges in Cancer Treatment. Journal of Ravishankar University (Part-B: Science), 37(2), pp. 268-287. DOI:DOI: https://doi.org/10.52228/JRUB.2024-37-2-19

REFERENCES

1. Goldman A, Kulkarni A, Kohandel M, Pandey P, Rao P, Natarajan SK, et al. Rationally Designed 2-in-1 Nanoparticles Can Overcome Adaptive Resistance in Cancer. ACS Nano [Internet]. 2016 Jun 28 [cited 2024 Dec 11];10(6):5823–34. Available from: https://pubmed.ncbi.nlm.nih.gov/27257911/

2. Han S, Chi Y, Yang Z, Ma J, Wang L. Tumor Microenvironment Regulation and Cancer Targeting Therapy Based on Nanoparticles. J Funct Biomater. 2023 Feb 28;14(3):136.

3. Adityan S, Tran M, Bhavsar C, Wu SY. Nano-therapeutics for modulating the tumour microenvironment: Design, development, and clinical translation. J Control Release [Internet]. 2020;327(April):512–32. Available from: https://doi.org/10.1016/j.jconrel.2020.08.016

4. Zheng R, Zhang S, Zeng H, Wang S, Sun K, Chen R, et al. Cancer incidence and mortality in China, 2016. J Natl Cancer Cent. 2022 Mar 1;2(1):1–9.

5. Al-Zoubi MS, Al-Zoubi RM. Nanomedicine tactics in cancer treatment: Challenge and hope. Crit Rev Oncol Hematol. 2022 Jun 1;174:103677.

6. Raju GSR, Pavitra E, Varaprasad GL, Bandaru SS, Nagaraju GP, Farran B, et al. Nanoparticles mediated tumor microenvironment modulation: current advances and applications. J Nanobiotechnology [Internet]. 2022 Dec 1 [cited 2024 Dec 11];20(1):1–20. Available from: https://jnanobiotechnology.biomedcentral.com/articles/10.1186/s12951-022-01476-9

7. Wu T, Dai Y. Tumor microenvironment and therapeutic response. Cancer Lett [Internet]. 2017 Feb 28 [cited 2024 Dec 11];387:61–8. Available from: https://pubmed.ncbi.nlm.nih.gov/26845449/

8. Feng Y, Tang Q, Wang B, Yang Q, Zhang Y, Lei L, et al. Targeting the tumor microenvironment with biomaterials for enhanced immunotherapeutic efficacy. J Nanobiotechnology [Internet]. 2024 Dec 1 [cited 2024 Dec 11];22(1). Available from: https://pubmed.ncbi.nlm.nih.gov/39605063/

9. Kim J, Hong J, Lee J, Fakhraei Lahiji S, Kim YH. Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy. J Control Release. 2021 Apr 10;332:109–26.

10. Shen S, Gao Y, Ouyang Z, Jia B, Shen M, Shi X. Photothermal-triggered dendrimer nanovaccines boost systemic antitumor immunity. J Control Release. 2023 Mar 1;355:171–83.

11. Afzal M, Ameeduzzafar, Alharbi KS, Alruwaili NK, Al-Abassi FA, Al-Malki AAL, et al. Nanomedicine in treatment of breast cancer – A challenge to conventional therapy. Semin Cancer Biol. 2021 Feb 1;69:279–92.

12. Bussard KM, Mutkus L, Stumpf K, Gomez-Manzano C, Marini FC. Tumor-associated stromal cells as key contributors to the tumor microenvironment. Breast Cancer Res [Internet]. 2016 Aug 11 [cited 2024 Dec 11];18(1). Available from: https://pubmed.ncbi.nlm.nih.gov/27515302/

13. Jin C, Wang K, Oppong-Gyebi A, Hu J. Application of nanotechnology in cancer diagnosis and therapy - A mini-review. Int J Med Sci. 2020;17(18):2964–73.

14. Nguyen VH, Kim HS, Ha JM, Hong Y, Choy HE, Min JJ. Genetically engineered Salmonella typhimurium as an imageable therapeutic probe for cancer. Cancer Res [Internet]. 2010 Jan 1 [cited 2024 Dec 11];70(1):18–23. Available from: https://pubmed.ncbi.nlm.nih.gov/20028866/

15. Mosleh-Shirazi S, Abbasi M, Moaddeli MR, Vaez A, Shafiee M, Kasaee SR, et al. Nanotechnology Advances in the Detection and Treatment of Cancer: An Overview. Nanotheranostics. 2022;6(4):400–23.

16. Dai Q, Bertleff-Zieschang N, Braunger JA, Björnmalm M, Cortez-Jugo C, Caruso F. Particle Targeting in Complex Biological Media. Adv Healthc Mater. 2018 Jan 10;7(1).

17. Navigating the Future: Advancements in Monoclonal Antibody Nanoparticle Therapy for Cancer. J Drug Deliv Sci Technol. 2024 Dec 6;106495.

18. Ray P. Curing Cancer with Nanotherapy Continues to be an Elusive Goal. J Immunol Sci. 2021;5(2):36–9.

19. Zeng L, Gowda BHJ, Ahmed MG, Abourehab MAS, Chen ZS, Zhang C, et al. Advancements in nanoparticle-based treatment approaches for skin cancer therapy. Mol Cancer [Internet]. 2023 Dec 1 [cited 2024 Dec 11];22(1). Available from: https://pubmed.ncbi.nlm.nih.gov/36635761/

20. Chen L, Hong W, Ren W, Xu T, Qian Z, He Z. Recent progress in targeted delivery vectors based on biomimetic nanoparticles. Signal Transduct Target Ther [Internet]. 2021 Dec 1 [cited 2024 Dec 11];6(1). Available from: https://pubmed.ncbi.nlm.nih.gov/34099630/

21. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin [Internet]. 2022 Jan [cited 2024 Dec 11];72(1):7–33. Available from: https://pubmed.ncbi.nlm.nih.gov/35020204/

22. Kulkarni JA, Witzigmann D, Chen S, Cullis PR, Van Der Meel R. Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics. Acc Chem Res. 2019 Sep 17;52(9):2435–44.

23. Riley RS, June CH, Langer R, Mitchell MJ. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov 2018 183 [Internet]. 2019 Jan 8 [cited 2024 Dec 11];18(3):175–96. Available from: https://www.nature.com/articles/s41573-018-0006-z

24. Lakshmanan VK, Jindal S, Packirisamy G, Ojha S, Lian S, Kaushik A, et al. Nanomedicine-based cancer immunotherapy: recent trends and future perspectives. Cancer Gene Ther. 2021 Sep 1;28(9):911–23.

25. Karahan HE, Wiraja C, Xu C, Wei J, Wang Y, Wang L, et al. Graphene Materials in Antimicrobial Nanomedicine: Current Status and Future Perspectives. Adv Healthc Mater. 2018 Jul 11;7(13).

Related Images: